MA54630B1 - N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives - Google Patents

N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Info

Publication number
MA54630B1
MA54630B1 MA54630A MA54630A MA54630B1 MA 54630 B1 MA54630 B1 MA 54630B1 MA 54630 A MA54630 A MA 54630A MA 54630 A MA54630 A MA 54630A MA 54630 B1 MA54630 B1 MA 54630B1
Authority
MA
Morocco
Prior art keywords
bis
treatment
neurodegenerative diseases
disease
mercaptoethyl isophthalamide
Prior art date
Application number
MA54630A
Other languages
English (en)
Other versions
MA54630A (fr
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of MA54630A publication Critical patent/MA54630A/fr
Publication of MA54630B1 publication Critical patent/MA54630B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Selon l'invention, il est proposé du n,n-bis-2-mercaptoéthyl isophtalamide, ou un sel ou dérivé pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans le traitement thérapeutique d'un trouble neurodégénératif, tel que la maladie d'alzheimer, la maladie de huntington et/ou la maladie latérale amyotrophique. Sclérose
MA54630A 2014-05-30 2020-02-06 N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives MA54630B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1409662.2A GB2526623A (en) 2014-05-30 2014-05-30 New pharmaceutical use

Publications (2)

Publication Number Publication Date
MA54630A MA54630A (fr) 2021-11-03
MA54630B1 true MA54630B1 (fr) 2023-01-31

Family

ID=51214502

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40065A MA40065B1 (fr) 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
MA54630A MA54630B1 (fr) 2014-05-30 2020-02-06 N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40065A MA40065B1 (fr) 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson

Country Status (17)

Country Link
US (4) US20170202791A1 (fr)
EP (2) EP3148588B1 (fr)
CY (1) CY1124509T1 (fr)
DK (2) DK3903774T3 (fr)
ES (2) ES2882977T3 (fr)
FI (1) FI3903774T3 (fr)
GB (1) GB2526623A (fr)
HR (2) HRP20211309T1 (fr)
HU (2) HUE060927T2 (fr)
LT (2) LT3148588T (fr)
MA (2) MA40065B1 (fr)
PL (2) PL3148588T3 (fr)
PT (2) PT3148588T (fr)
RS (2) RS62095B1 (fr)
SI (2) SI3148588T1 (fr)
SM (2) SMT202300015T1 (fr)
WO (1) WO2015181567A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) * 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
JP2013505963A (ja) 2009-09-28 2013-02-21 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション 汚染された環境から元素を除去するチオール含有化合物およびその使用方法
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
DK3903774T3 (da) 2023-01-16
RS63859B1 (sr) 2023-01-31
HRP20230105T1 (hr) 2023-03-17
SMT202300015T1 (it) 2023-03-17
GB2526623A (en) 2015-12-02
US20180250247A1 (en) 2018-09-06
US20170202791A1 (en) 2017-07-20
PL3903774T3 (pl) 2023-03-13
FI3903774T3 (fi) 2023-04-12
SI3903774T1 (sl) 2023-03-31
MA40065A (fr) 2021-05-19
EP3903774A1 (fr) 2021-11-03
RS62095B1 (sr) 2021-08-31
HUE060927T2 (hu) 2023-04-28
US12128017B2 (en) 2024-10-29
WO2015181567A1 (fr) 2015-12-03
EP3148588B1 (fr) 2021-06-23
GB201409662D0 (en) 2014-07-16
US20220287994A1 (en) 2022-09-15
ES2882977T3 (es) 2021-12-03
PL3148588T3 (pl) 2021-12-13
US11628151B2 (en) 2023-04-18
EP3903774B1 (fr) 2022-11-09
PT3903774T (pt) 2022-12-23
SI3148588T1 (sl) 2022-01-31
MA54630A (fr) 2021-11-03
MA40065B1 (fr) 2021-09-30
DK3148588T3 (en) 2021-07-26
ES2938080T3 (es) 2023-04-04
SMT202100453T1 (it) 2021-09-14
US20230013704A1 (en) 2023-01-19
HRP20211309T1 (hr) 2021-11-26
EP3148588A1 (fr) 2017-04-05
LT3903774T (lt) 2023-01-10
LT3148588T (lt) 2021-08-10
PT3148588T (pt) 2021-07-15
CY1124509T1 (el) 2022-07-22
HUE055575T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA53937A (fr) Compositions comprenant des souches bactériennes
MA46018A (fr) Activateurs d'édition du génome
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
AR110747A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
EP3400061A4 (fr) Système de photothérapie pour le traitement d'affections nasales
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
EP3728567A4 (fr) Procédés pour le développement de produits pharmaceutiques pour le traitement d'affections neurodégénératives
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
EP3730144A4 (fr) Agent pour le traitement d'une maladie du système nerveux
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d'alzheimer
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3452047A4 (fr) Compositions pour le traitement de la douleur vulvaire et périnéale chronique et des symptomes et affections associés à celle-ci
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
EP3628008A4 (fr) Compositions et méthodes pour le traitement de la maladie d'alzheimer
MX2016008968A (es) Compuestos organicos.
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39833B1 (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide